Degarelix

Degarelix (Firmagon) — GnRH Receptor Antagonist

Evidence & Status

  • FDA Approved
  • Strong Human Evidence
  • Established

At a Glance

A GnRH antagonist represented by FIRMAGON for advanced prostate cancer; it should not be described as proven cardiovascular-superior to GnRH agonists.

Plain English

Degarelix is a prescription cancer-treatment product. One comparator study supports its no-initial-surge mechanism, while a cardiovascular trial stopped early and cannot settle superiority.

Overview

Degarelix is a GnRH receptor antagonist represented by the FIRMAGON prescription product for advanced prostate cancer. In CS21, degarelix achieved testosterone suppression without the initial testosterone surge associated with the leuprolide comparator in that trial. PRONOUNCE compared cardiovascular safety in men with prostate cancer and established atherosclerotic cardiovascular disease, but was terminated early and did not prove cardiovascular superiority.

Research Summary

CS21 provides comparator-specific evidence for rapid testosterone suppression without an initial surge. A short-term cardiovascular safety comparison has limited interpretability, and PRONOUNCE's early termination means it does not show cardiovascular superiority. FIRMAGON labeling remains the source for the represented product's indication, administration, and warnings.

Research Areas

  • Prostate cancer
  • Androgen deprivation
  • GnRH receptor pharmacology
  • Testosterone suppression
  • Cardiovascular safety research

Safety & Risks

Serious Risks

  • QT/QTc prolongation may occur with androgen-deprivation therapy; product labeling advises clinical consideration and monitoring.
  • Injection-site reactions and hypersensitivity reactions are described in FIRMAGON labeling.
  • PRONOUNCE was terminated early and does not establish cardiovascular superiority of degarelix.
United States
FIRMAGON is an FDA-labeled prescription product for advanced prostate cancer; this record does not establish cardiovascular superiority over GnRH agonists.
United Kingdom
Not assessed in this record.
Australia
Not assessed in this record.
Canada
Not assessed in this record.